Added to YB: 2026-09-09
Pitch date: 2026-09-07
TENX [bullish]
Tenax Therapeutics, Inc.
+1.54%
current return
Author Info
Kelin Research shares independent research on listed life sciences companies. I work from primary sources, clinical data and back-of-the-envelope valuation to answer three questions: what does the science say, what is the market pricing in, and what would prove or kill the thesis? Sign up for the newsletter.
Company Info
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States.
Market Cap
$111.1M
Pitch Price
$1.95
Price Target
N/A
Dividend
N/A
EV/EBITDA
N/A
P/E
-1.32
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Speculative Series: Tenax Therapeutics Inc (TENX)
TENX (hold): Hold a 1–2% speculative position through the August 2026 LEVEL readout: at roughly $13, estimated coin-flip odds compare with an implied success probability in the mid-20s. HELP’s 29.3m 6MWD signal supports the bet, but came from a secondary endpoint in a tiny enriched study that missed its primary endpoint. Failure could erase 80–90% of equity value, while a credible 15–20m benefit could support $35–60 per share.
Read full article (6 min)